In chronic myeloid leukemia (CML), the presence of a specific marker, the Philadelphia chromosome, together with the corresponding molecular marker (BCR-ABL fusion transcripts) provides a unique opportunity for the monitoring of the disease, at diagnosis and during therapy [14]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.